The estimated Net Worth of Kenneth J Zuerblis is at least $142 millier dollars as of 2 September 2014. Kenneth Zuerblis owns over 1,000 units of Stemline Therapeutics stock worth over $141,522 and over the last 14 years Kenneth sold STML stock worth over $0.
Sign up
Kenneth Zuerblis STML stock SEC Form 4 insiders trading
Kenneth has made over 2 trades of the Stemline Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently Kenneth bought 1,000 units of STML stock worth $11,140 on 2 September 2014.
The largest trade Kenneth's ever made was buying 3,000 units of Stemline Therapeutics stock on 29 May 2013 worth over $48,030. On average, Kenneth trades about 333 units every 38 days since 2010. As of 2 September 2014 Kenneth still owns at least 11,963 units of Stemline Therapeutics stock.
You can see the complete history of Kenneth Zuerblis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kenneth Zuerblis's mailing address?
Kenneth's mailing address filed with the SEC is C/O STEMLINE THERAPEUTICS, INC, 750 LEXINGTON AVENUE, ELEVENTH FLOOR, NEW YORK, NY, 10022.
Insiders trading at Stemline Therapeutics
Over the last 12 years, insiders at Stemline Therapeutics have traded over $12,490,046 worth of Stemline Therapeutics stock and bought 10,500 units worth $128,270 . The most active insiders traders include Eric Dobmeier, Kenneth Hoberman et Ivan Bergstein. On average, Stemline Therapeutics executives and independent directors trade stock every 29 days with the average trade being worth of $169,110. The most recent stock trade was executed by Robert Francomano on 4 May 2020, trading 272 units of STML stock currently worth $3,131.
What does Stemline Therapeutics do?
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
What does Stemline Therapeutics's logo look like?
Complete history of Kenneth Zuerblis stock trades at Immunomedics et Stemline Therapeutics
Stemline Therapeutics executives and stock owners
Stemline Therapeutics executives and other stock owners filed with the SEC include:
-
Eric Dobmeier,
Director -
Ron Bentsur,
Director -
Alan S Forman,
Director -
Kenneth Hoberman,
Chief Operating Officer -
Kenneth J Zuerblis,
Director -
David Gionco,
Chief Accounting Officer -
J Kevin Buchi,
Director -
Eric K Rowinsky,
Chief Medical Officer -
Ivan Bergstein,
Chief Executive Officer -
Robert Francomano,
Chief Commercial Officer -
Mark Sard,
Director -
Daniel Hume,
Director -
Darren S Cline,
Director -
Stephen P Hall,
Chief Accounting Officer